Literature DB >> 3014529

Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus.

R L Willey, R A Rutledge, S Dias, T Folks, T Theodore, C E Buckler, M A Martin.   

Abstract

The nucleotide sequences of the envelope genes of an African and a North American acquired immunodeficiency syndrome (AIDS) viral isolate have been determined. When their deduced amino acid sequences were aligned with the envelopes of the lymphoadenopathy and AIDS-associated retrovirus isolates, conserved and divergent regions were readily identified. Hypervariable stretches of 28-74 amino acids, exhibiting 20-30% amino acid identity at each position and characterized by reciprocal insertions and deletions, were confined to the gp120 external envelope protein. The origin and clinical implications of the AIDS viral env gene diversity are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014529      PMCID: PMC323885          DOI: 10.1073/pnas.83.14.5038

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

2.  Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.

Authors:  B H Hahn; M A Gonda; G M Shaw; M Popovic; J A Hoxie; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

3.  Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

Authors:  J Sodroski; R Patarca; C Rosen; F Wong-Staal; W Haseltine
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

4.  HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients.

Authors:  R Crowl; K Ganguly; M Gordon; R Conroy; M Schaber; R Kramer; G Shaw; F Wong-Staal; E P Reddy
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus.

Authors:  T Folks; S Benn; A Rabson; T Theodore; M D Hoggan; M Martin; M Lightfoote; K Sell
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

7.  A rapid single-stranded cloning strategy for producing a sequential series of overlapping clones for use in DNA sequencing: application to sequencing the corn mitochondrial 18 S rDNA.

Authors:  R M Dale; B A McClure; J P Houchins
Journal:  Plasmid       Date:  1985-01       Impact factor: 3.466

8.  Nucleotide sequence of a full-length human endogenous retroviral segment.

Authors:  R Repaske; P E Steele; R R O'Neill; A B Rabson; M A Martin
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

9.  Genomic diversity of human T-lymphotropic virus type III (HTLV-III).

Authors:  F Wong-Staal; G M Shaw; B H Hahn; S Z Salahuddin; M Popovic; P Markham; R Redfield; R C Gallo
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

10.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

View more
  86 in total

1.  Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.

Authors:  W R Lee; W J Syu; B Du; M Matsuda; S Tan; A Wolf; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology.

Authors:  F Clavel; J M Orenstein
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses.

Authors:  P R Donahue; E A Hoover; G A Beltz; N Riedel; V M Hirsch; J Overbaugh; J I Mullins
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

Authors:  A Valenzuela; J Blanco; B Krust; R Franco; A G Hovanessian
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection.

Authors:  Patrick R Harrington; Julie A E Nelson; Kathryn M Kitrinos; Ronald Swanstrom
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

6.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

7.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

Review 8.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

9.  Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

Authors:  Julie I Jay; Bonnie E Lai; David G Myszka; Alamelu Mahalingam; Kris Langheinrich; David F Katz; Patrick F Kiser
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

Review 10.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.